Low-dose lithium for mild cognitive impairment
Peer-Reviewed Publication
Updates every hour. Last Updated: 21-Jun-2026 21:16 ET (22-Jun-2026 01:16 GMT/UTC)
An exploratory clinical trial from the University of Pittsburgh suggests that low‑dose oral lithium may help slow the decline of verbal memory, or ability to remember and recall words and sentences, in older adults with mild cognitive impairment, particularly among those with evidence of amyloid beta—one of the hallmark biomarkers of Alzheimer’s disease.
A new analysis using data from the Department of Veterans Affairs’ Million Veteran Program (MVP) found individuals living with type 2 diabetes had a substantially lower risk of major adverse cardiovascular events when they used a GLP‑1 receptor agonist in combination with several healthy lifestyle habits. The study represents the first large‑scale effort to evaluate how medication and lifestyle factors jointly influence heart health in this population.
The findings have implications for treatment. Knowing ahead of time which resistance mechanism a patient’s tumor is likely to implement can guide treatment decisions to prevent or reduce resistance.
Building functional human muscle in the laboratory has long been a goal of regenerative medicine, but one stubborn obstacle remains: real muscle is not just a mass of cells. Its strength and function depend on exquisitely ordered myofibers, all aligned in precise directions that vary from one muscle to another. Reproducing that internal order has proved far harder than shaping muscle tissue into the right external form.
In the International Journal of Extreme Manufacturing, a research team from Xi'an Jiaotong University has now found a way to solve both problems at once. By using electric forces during the electrohydrodynamic bioprinting process, they have created living muscle tissues whose cells naturally line up just as they do in the human body, showing how electric forces can be used not just to precisely bioprint tissue, but to quietly instruct cells how to organize themselves.
Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced the pilot launch of its Automated AI-Driven Partnering System. This first of its kind business development automation platform is designed to help biotechnology companies partner more efficiently, allowing them to increase engagement, manage due diligence and operate their pipelines on a greater scale. The new system expands Insilico’s applied AI capabilities and introduces an infrastructure that can utilize partnering decks and publications, respond to scientific or diligence questions, support data room management, and streamline standard business development activities end to end.